ClinicalTrials.gg
CompletedNCT06039722SCENA-AFUpdated Jun 19, 2025

Safety-and-effectiveness Clinical Evaluation of Nanosecond-pulse Ablation for Atrial Fibrillation

An interventional study of Pulse ablation catheter in Paroxysmal Atrial Fibrillation, sponsored by Shenzhen Pulsecare Medical Technology Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-06-19.

Sponsored by Shenzhen Pulsecare Medical Technology Co., Ltd. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Nov 2022, registered Sep 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
166
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 377 studies in Atrial Fibrillation with a site in China — 162 open to participants now, 183 under way, 4 of them phase 3. Atrial Fibrillation · China.

Enrollment
159th of 256
166 · median 235
Started
2022
with 39 others
No phase
200 of 377
100 open now
Registered
203rd of 377
by date

Among the 377 studies in Atrial Fibrillation with a site in China, this one is the 159th largest by enrollment of the 256 interventional ones that give a count, is one of 40 that started in 2022, is one of 200 with no phase, and was the 203rd registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

162 of the 377 studies in Atrial Fibrillation with a site in China are open now. Recruiting first, the newest first:

157 more — sign in →

All 162 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 377 studies in Atrial Fibrillation with a site in China, or all of them as a file.
02

Study summary

This study is expected to include 166 subjects and Conducted at 11 research centers;The expected 12 month treatment success rate of using research instruments is 65%.

Principle evaluation indexes:

  1. Immediate success rate of surgery Immediately success of the surgery: complete pulmonary vein electrical isolation was achieved after ablation.
  2. Immediate success rate of surgery=number of patients with immediate success of surgery/number of cases in subjects × 100%
  3. Treatment success rate at 12 months after surgery Treatment success: Between 3 months and 12 months after ablation, there were no episodes of atrial fibrillation/atrial flutter/atrial tachycardia (duration ≥ 30 seconds, with clear electrocardiogram confirmation) without the use of antiarrhythmic drugs.

Treatment success rate=number of successful cases of postoperative treatment in subjects/number of cases in subjects × 100%

Secondary evaluation indexes:

  1. The occurrence of hospitalization or emergency treatment due to symptoms caused by atrial arrhythmias during follow-up at 6 and 12 months after surgery;
  2. Device performance evaluation;

Safety evaluation indexes:

  1. The occurrence of death, stroke, or transient ischemic attack;
  2. The occurrence of surgical related complications, such as vascular puncture complications (pseudoaneurysm, arteriovenous fistula, etc.), heart perforation, atrial esophageal fistula, phrenic nerve injury, pulmonary vein stenosis (symptomatic), etc;
  3. Clinically significant vital signs and related examinations;
  4. The occurrence of other adverse events and serious adverse events during the trial period.
03

Conditions studied

  • Paroxysmal Atrial Fibrillation

Browse trials for

Keywords

  • Pulse Field Ablation Catheter
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must meet all of the following conditions to be enrolled:

  1. 18 to 80 years of age, gender is not limited
  2. Patients with a clinical diagnosis of paroxysmal atrial fibrillation confirmed by
  3. Patients who were to undergo catheter ablation of atrial fibrillation
  4. Those who agreed to participate in this study and voluntarily signed the form

Exclusion criteria

Exclusion Criteria:

Subjects were excluded if they met one of the following conditions:

  1. Patients who have had ablation for atrial fibrillation
  2. Patients with (LVEF) \<35%.
  3. Patients with an anteroposterior diameter of the left atrium (echocardiography) >50 mm
  4. Preoperative detection of a definite thrombus in the left atrium
  5. Patients with cardiac function class () III-IV
  6. Patients with second-degree (type II) or third-degree atrioventricular block
  7. Patients with significant congenital heart defects (including atrial septal defect, ventricular septal defect, arterial ductus arteriosus, transposition ofthe grea, or severe pulmonicvalve, but not including foramen ovale persistens)
  8. Patients with implanted prosthetic valves or the presence of severe heart valve disease, who are not suitable for ablation for atrial fibrillation
  9. Patients with artificial cardiac pacemaker or implantable cardioverter defibrillator (ICDs)
  10. Patients diagnosed with hypertrophic obstructive cardiomyopathy, , or myxoma
  11. Patients who need to undergo left atrial appendage closure in the same surgery
  12. Patients found to have atrial flutter preoperatively and judged unsuitable by the investigators, or patients with atrial parasystolic tachycardia (non-pulmonary venous origin) or paroxysmal supraventricular tachycardia
  13. Patients with active systemic infection who are judged unsuitable for interventional therapy by the investigators
  14. Patients with systemic bleeding tendencies that preclude surgery or patients with renal failure undergoing hemodialysis
  15. Patients who have had a myocardial infarction or any interventional/open heart surgery (except coronary angiography) within 3 months
  16. Patients who have had a stroke (except asymptomatic stroke) or within 3 months
  17. Patients with significant to interventional procedures or with an expected survival of \<1 year who are judged by the investigator to be incapable of undergoing ablative procedures
  18. Females who are pregnant or breastfeeding or who are planning to have children during the study period
  19. Patients who have participated in a clinical trial of another drug or medical device within 3 months
  20. Patients who, in the opinion of the investigator, are not suitable for participation in this clinical trial
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
166 participants (actual)

Study arms

  • Experimental
    experimental group

    Each subject underwent pulse ablation catheter ablation

    Device: Pulse ablation catheter

Interventions

  • DevicePulse ablation catheter

    Pulse ablation catheter is used to ablate the junction of left atrium and pulmonary vein, removing pulmonary vein potential

06

What researchers measure

Primary outcomes

  1. Immediate success rate of surgery

    Immediate success rate of surgery Immediately success of the surgery: complete pulmonary vein electrical isolation was achieved after ablation. Immediate success rate of surgery Immediately success of the surgery: complete pulmonary vein electrical isolation was achieved after ablation. Immediate success rate of surgery Immediately success of the surgery: complete pulmonary vein electrical isolation was achieved after ablation. Immediate success rate of surgery=number of patients with immediate success of surgery/number of cases in subjects × 100%

    Time frame: After surgery 20 minutes later

  2. Treatment success rate

    Treatment success rate at 12 months after surgery Treatment success: Between 3 months and 12 months after ablation, there were no episodes of atrial fibrillation/atrial flutter/atrial tachycardia (duration ≥ 30 seconds, with clear electrocardiogram confirmation) without the use of antiarrhythmic drugs. Treatment success rate=number of successful cases of postoperative treatment in subjects/number of cases in subjects × 100%

    Time frame: Between 3 months and 12 months after ablation

Secondary outcomes

  1. numer of cases of the the occurrence of hospitalization or emergency treatment

    The occurrence of hospitalization or emergency treatment due to symptoms caused by atrial arrhythmias during follow-up at 6 and 12 months after surgery;

    Time frame: Between 0 months and 12 months after ablation

  2. Device performance evaluation

    Device defects of the clinical trial equipment

    Time frame: surgery period

07

Study locations

1 site
  • the Second Affiliated Hospital of Sun Yat-sen University (Sun Yat-sen Memorial Hospital)
    Guangzhou, Guangdong 510120, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2022 to primary completion in Aug 2024, 21 months.

Of 255 industry-sponsored interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 36. This study's 21 months is close to that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2023
First posted
Sep 15, 2023
StartActual
Nov 3, 2022
Primary completionActual
Aug 29, 2024
CompletionActual
Aug 29, 2024
Last update
Jun 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06039722
Lead sponsor
Shenzhen Pulsecare Medical Technology Co., Ltd.
Responsible party
Sponsor
First posted
Sep 15, 2023
Start date
Nov 3, 2022
Primary completion
Aug 29, 2024
Completion
Aug 29, 2024
Last update
Jun 19, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion